Výsledky vyhledávání - "Jens Bodo Huober"

Akademický článek

Adaptive immune signature in HER2-positive breast cancer in NCCTG (Alliance) N9831 and NeoALTTO trials

Publikováno v: npj Breast Cancer, Vol 8, Iss 1, Pp 1-8 (2022)

Abstract Trastuzumab acts in part through the adaptive immune system. Previous studies showed that enrichment of immune-related gene expression was associated with improved outcomes in HER2-positive (HER2+) breast cancer. However, the role of the imm

Externí odkaz: https://doaj.org/article/c541e25cb1954a448e8d1d99ad81395d

Zobrazit plný text záznamu

Prognostic and predictive implications of the intrinsic subtypes and gene expression signatures in early-stage HER2+ breast cancer: A pooled analysis of CALGB 40601, NeoALTTO, and NSABP B-41 trials

Publikováno v: Journal of Clinical Oncology. 40:509-509

509 Background: Several biologic features are implicated in the differences in response and survival to dual (trastuzumab and lapatinib [HL]) vs. single (trastuzumab [H]) HER2-blockade across neoadjuvant trials in early-stage HER2+ breast cancer. We

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::79387c6bd37f0bcb6b32118188a4c09b
https://doi.org/10.1200/jco.2022.40.16_suppl.509

Zobrazit plný text záznamu

Biomarkers for response to immunotherapy in triple-negative breast cancer: Differences between survival and pCR biomarkers

Publikováno v: Journal of Clinical Oncology. 40:583-583

583 Background: Immunotherapy is entering clinical practice as a promising new neoadjuvant therapeutic approach in triple-negative breast cancer, and it is important to identify biomarkers to focus this therapy on those patients that have the highest

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::f876e533287678a0cc53b4500e8dcc7a
https://doi.org/10.1200/jco.2022.40.16_suppl.583

Zobrazit plný text záznamu

Low TMB as predictor for additional benefit from neoadjuvant immune checkpoint inhibition in triple-negative breast cancer

Autor: Thomas Karn, Carsten Denkert, Julia Rey, Karsten Ernst Weber, Uwe Holtrich, Claus Hanusch, Bruno Valentin Sinn, Paul Jank, Jens Bodo Huober, Jens U. Blohmer, Wolfgang D. Schmitt, Marion van Mackelenbergh, Christian Schem, Elmar Stickeler, Christian Jackisch, Michael Untch, Andreas Schneeweiss, Sibylle Loibl

Publikováno v: Journal of Clinical Oncology. 40:581-581

581 Background: It is commonly anticipated that a high tumor mutational burden (TMB) is a predictor of response to immune checkpoint blockade (ICB). We previously showed that triple-negative breast cancer (TNBC) from the GeparNuevo study with high TM

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::ec1c9d178098e90896556e3540cb965a
https://doi.org/10.1200/jco.2022.40.16_suppl.581

Zobrazit plný text záznamu

GeparOLA: A randomized phase II trial to assess the efficacy of paclitaxel and olaparib in comparison to paclitaxel/carboplatin followed by epirubicin/cyclophosphamide as neoadjuvant chemotherapy in patients (pts) with HER2-negative early breast cancer (BC) and homologous recombination deficiency (HRD)

Autor: Peter A. Fasching, Christian Jackisch, Kerstin Rhiem, Andreas Schneeweiss, Peter Klare, Claus Hanusch, Jens Bodo Huober, Theresa Link, Michael Untch, Sabine Schmatloch, Carsten Denkert, Andrea Stefek, Christoph Uleer, Gabriele Doering, Knut Engels, Fenja Seither, Jens Uwe Blohmer, Sibylle Loibl

Publikováno v: Journal of Clinical Oncology. 37:506-506

506 Background: The efficacy and toxicity of olaparib in early BC pts with homologous DNA repair deficiency (here defined as HRD score high tumors +/- germline (g) or tumor (t) BRCA mutation) is not well described. GeparOLA investigates olaparib in H

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::9688d515062503f0458bf74e062ecb21
https://doi.org/10.1200/jco.2019.37.15_suppl.506

Zobrazit plný text záznamu

A randomized phase II neoadjuvant study (GeparNuevo) to investigate the addition of durvalumab, a PD-L1 antibody, to a taxane-anthracycline containing chemotherapy in triple negative breast cancer (TNBC)

Publikováno v: Journal of Clinical Oncology. 35:3062-3062

3062 Background: Adding an anti-PD-L1 checkpoint inhibitor durvalumab to standard chemotherapy (CT) may increase pathological complete response (pCR) in patients (pts) with TNBC. Methods: GeparNuevo randomizes pts to durvalumab (D) 1.5 g i.v. or plac

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::2d27be06c9dc85aa25c01815b7ddb1bc
https://doi.org/10.1200/jco.2017.35.15_suppl.3062

Zobrazit plný text záznamu

A randomized phase III trial comparing two dose-dense, dose-intensified approaches (EPC and PM(Cb)) for neoadjuvant treatment of patients with high-risk early breast cancer (GeparOcto)

Autor: Andreas Schneeweiss, Volker Moebus, Jens Uwe Blohmer, Serban Dan Costa, Carsten Denkert, Holger Eidtmann, Claus Hanusch, Joern Hilfrich, Jens Bodo Huober, Christian Jackisch, Stefan Paepke, Sherko Kümmel, Hans Tesch, Michael Untch, Sibylle Loibl, Gunter Von Minckwitz

Publikováno v: Journal of Clinical Oncology. 33:TPS1101-TPS1101

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::d5dbff46f68a382c0854377e76b19cc5
https://doi.org/10.1200/jco.2015.33.15_suppl.tps1101

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání